Epizyme is a clinical-stage biopharmaceutical company developing epigenetic medicines for the treatment of cancer and other serious diseases by focusing on the genetic drivers of disease. The Company’s lead product candidate, tazemetostat, is an oral, first-in-class inhibojtor of the EZH2 histone methyltransferase (HMT) and is being studied in various cancer types and settings, including follicular lymphoma (FL) and epithelioid sarcoma (ES). The Company is also developing EZM8266, a novel G9a inhibitor, for sickle cell disease (SCD).